PISANI, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 5.436
EU - Europa 3.792
AS - Asia 3.021
SA - Sud America 1.715
AF - Africa 77
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 14.054
Nazione #
US - Stati Uniti d'America 5.339
BR - Brasile 1.532
SG - Singapore 1.296
IE - Irlanda 959
CN - Cina 802
SE - Svezia 758
IT - Italia 479
HK - Hong Kong 437
UA - Ucraina 406
DE - Germania 376
FI - Finlandia 197
VN - Vietnam 169
RU - Federazione Russa 159
GB - Regno Unito 146
FR - Francia 97
AR - Argentina 69
IN - India 64
PL - Polonia 58
TR - Turchia 43
MX - Messico 40
IQ - Iraq 39
AT - Austria 33
CA - Canada 33
EC - Ecuador 32
NL - Olanda 29
BD - Bangladesh 28
BE - Belgio 28
UZ - Uzbekistan 23
ZA - Sudafrica 23
VE - Venezuela 19
MA - Marocco 18
JP - Giappone 17
PY - Paraguay 14
CO - Colombia 12
PK - Pakistan 12
ID - Indonesia 11
PE - Perù 11
CL - Cile 10
IR - Iran 9
LT - Lituania 9
TN - Tunisia 9
UY - Uruguay 9
CZ - Repubblica Ceca 8
ES - Italia 8
JO - Giordania 7
KZ - Kazakistan 7
OM - Oman 7
PA - Panama 7
BO - Bolivia 6
IL - Israele 6
JM - Giamaica 6
KE - Kenya 6
AU - Australia 5
AZ - Azerbaigian 5
CH - Svizzera 5
EG - Egitto 5
KR - Corea 5
RS - Serbia 5
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
HN - Honduras 4
LV - Lettonia 4
NZ - Nuova Zelanda 4
AO - Angola 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EU - Europa 3
GR - Grecia 3
RO - Romania 3
AM - Armenia 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CY - Cipro 2
GE - Georgia 2
HR - Croazia 2
KG - Kirghizistan 2
KW - Kuwait 2
LB - Libano 2
MK - Macedonia 2
NI - Nicaragua 2
PH - Filippine 2
PS - Palestinian Territory 2
SI - Slovenia 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CR - Costa Rica 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GY - Guiana 1
HU - Ungheria 1
KH - Cambogia 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
Totale 14.044
Città #
Dublin 957
Jacksonville 828
Chandler 699
Singapore 539
Dallas 491
Hong Kong 437
Ashburn 391
Beijing 375
Nyköping 321
Dearborn 193
Princeton 189
Cambridge 179
Los Angeles 148
Des Moines 146
Medford 125
Ann Arbor 116
São Paulo 115
The Dalles 108
Boardman 98
Buffalo 89
Ho Chi Minh City 71
New York 70
Warsaw 55
Rio de Janeiro 53
Moscow 51
Messina 47
Wilmington 47
Woodbridge 47
Tianjin 45
Munich 44
San Mateo 40
Shenyang 40
Belo Horizonte 37
Hanoi 36
Jinan 35
Milan 32
Houston 30
Redondo Beach 30
Rome 29
Nanjing 28
Brussels 27
Curitiba 27
Vienna 24
Bremen 22
Pune 22
Salvador 22
Seattle 22
Hebei 20
Tashkent 20
Brasília 19
Campinas 19
Porto Alegre 19
Stockholm 17
Norwalk 16
Zhengzhou 16
Brooklyn 15
Ningbo 15
Amsterdam 14
Fortaleza 14
Guarulhos 14
Jiaxing 14
Lancaster 14
Montreal 14
Ribeirão Preto 14
Chicago 13
Frankfurt am Main 13
Guayaquil 13
Helsinki 13
Santa Clara 13
Chennai 12
Denver 12
Fuzhou 12
Haikou 12
Hangzhou 12
Naples 12
Poplar 12
Tokyo 12
Atlanta 11
Caruaru 11
Goiânia 11
Istanbul 11
Johannesburg 11
Manchester 11
Recife 11
London 10
Mexico City 10
Mumbai 10
Phoenix 10
Santo André 10
Sorocaba 10
São José dos Campos 10
Ardabil 9
Bauru 9
Campo Grande 9
Duque de Caxias 9
Maceió 9
Quito 9
Washington 9
Águas Lindas de Goiás 9
Ankara 8
Totale 8.239
Nome #
" Stato confusionale di probabile natura iatrogena"; " Verosimile screzio psicotico"; " Sindrome Cefalalgica"; " Disturbo d'Ansia". Varie ipotesi ed una sola diagnosi: SENC 351
Antiepileptic drugs and MTHFR Polymorphisms influence hyper-homocysteinemia recurrence in epileptic patients 149
"Valproic acid-amitriptyline interaction in man 149
Rischio di iperomocisteinemia in pazienti con Epilessia, portatori del diplotipo C677T/A1298C della MTHFR 143
Distribuzione di due polimorfismi genici della MTHFR in pazienti con Epilessia e correlazione con i livelli serici di omocisteina 136
ALLOPURINOL AS ADD-ON THERAPY IN REFRACTORY EPILEPSY - A DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY 128
ATTENTION CHARACTERIZATION IN PATIENTS WITH FRONTAL AND TEMPORAL LOBE EPILEPSY 126
FORCED NORMALISATION: OBSERVATION WITH NEW ANTIEPILEPTIC DRUGS 125
beneficial effect of donezepil in a malnourished surgical patient with severe nonalcoholic wernicke's encephalopathy 123
Aspetti neuropsichiatrici dell'epilessia 116
Non-convulsive status epilepticus after ischemic stroke: a hospital-based stroke cohort study 116
FORCED NORMALISATION: A RETROSPECTIVE ANALYSIS OF RISK FACTORS 114
Hyperhomocysteinemia and retinal vascular changes in patients with epilepsy. 114
Controllo totale di crisi con l’associazione lamotrigina-gabapentin in un caso di epilessia sintomatica. 113
Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia 112
Differential distribution of epilepsy in patients with different types of dementia: a single-centre, retrospective study 112
An epidemiological study of the clinical impact of pharmacokinetic anticonvulsant drug interactions based on serum drug level analysis 111
Normalizzazione forzata e fattori di rischio: un'analisi retrospettiva 109
Antidepressant effect of vagal nerve stimulation in epilepsy patients: a systematic review 107
Hyperhomocysteinemia in patients with epilepsy: does it play a role in the pathogenesis of brain atrophy? A preliminary report. 106
Effect of viloxazine on serum carbamazepine levels in epileptic patients 106
A sensitive gas chromatograpic assay for the determination of serum viloxazine concetration using a nitrogen-phosphorus selective detector". Ther. Drug Monit., 6:484-488, 1984. 106
Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study 106
Antidepressant drugs and seizure susceptibility: From in vitro data to clinical practice 105
Carbamazepine-viloxazine interaction in patients with epilepsy 105
A study on the metabolism of dipropylacetamide to dipropylacetic acid in rats 102
Is retinal assessment useful in epileptic patients with hyperhomocysteinemia? 100
CARBAMAZEPINE VALNOCTAMIDE INTERACTION IN EPILEPTIC PATIENTS - IN-VITRO IN-VIVO CORRELATION 99
THE EFFECT OF COMBINING VIGABATRIN AND TIAGABINE, TWO DRUGS WITH COMPLEMENTARY GABAERGIC MECHANISMS, AGAINST NMDA-INDUCED EXCITOTOXICITY 97
The contribution of inter-ictal SPECT in the evaluation of patients with epilepsy: Possible additional uses on the basis of selected cases [Il contributo della SPECT inter-critica nella valutazione del paziente con epilessia: Possibili ulteriori indicazioni sulla base di alcuni casi selezionati] 97
Dipropylacetic acid plasma levels; diurnal fluctuations during chronic treatment with dipropylacetamide 96
Effect of valpromide on the pharmacokinetics of Carbamazepine-10,11-epoxide 96
Repetitive transcranial magnetic stimulation induced slow wave activity modification: A possible role in disorder of consciousness differential diagnosis? 96
Diurnal fluctuations in plasma drug levels:studies with valproic acid and carbamazepine 95
Prevenzione dell’epilettogenesi: revisione della letteratura, raccomandazioni terapeutiche, proposte di ricerca 95
The effect of lamotrigine on peripheral nerves. 93
Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs. 93
Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST) 92
Effects of psychotropic drugs on seizure threshold 92
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD 90
Accidents in patients with epilepsy: types, circumstances, and complications: a European cohort study 90
Identification of amoebae in the CSF in a patient with meningoencephalitis. 90
Neuroprotective effects of levetiracetam against kainic acid toxicity are mediated by inhibition of lipid peroxidation 89
INFLUENCE OF COMEDICATION ON THE METABOLISM OF VALPROATE 89
Meccanismi eccitotossici in un modello sperimentale in vitro: effetti della lamotrigina sul rilascio di amminoacidi eccitatori 89
A critical role of NO/cGMP/PKG dependent pathway in hippocampal post-ischemic LTP: modulation by zonisamide 89
Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs 89
Antiepileptic drug comedications in clinical practice 88
Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. 88
Lamotrigina ed effetti elettrofisiologici sul sistema nervoso periferico. 87
Differential interactions of valproic acid and valpromide with Carbamazepine in man 87
Prime esperienze su efficacia e tollerabilità della tiagabina in pazienti con epilessia farmacoresistente 86
Effetto della viloxazina sui livelli ematici di oxcarbazepina e dei relativi metaboliti 86
Ruolo dei farmaci antiepilettici nella neuroprotezione da ischemia cerebrale 85
Lamotrigina ed effetti elettrofisiologici sul sistema nervoso periferico 85
Evaluation of Tricyclic Antidepressant Plasma Levels by an Automated Enzyme Immunoassay (EMIT) in Comparison to a High-Performance Liquid Chromatographic Method 84
Attivita' parossistica ed agenti farmacologici: attivazione ed inibizione 84
Il concetto di normalizzazione forzata in epilettologia 81
Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment 81
Single-dose kinetics of primidone in acute viral hepatitis 81
Disturbi del linguaggio e farmaci antiepilettici: analisi prospettica dei possibili fattori di rischio 81
ELEVATION OF PLASMA PHENYTOIN BY VILOXAZINE IN EPILEPTIC PATIENTS - A CLINICALLY SIGNIFICANT DRUG-INTERACTION 80
Pharmacokinetics and therapeutic plasma monitoring of antiepileptic drugs 80
Neuroprotective effect of remacemide hydrochloride against NMDA-induced excitotoxicity in isolated chick embryo retina 79
Crisi epilettiche indotte dall’assunzione di leflunamide in pazienti in terapia con carbamazepina 79
Specific Patient Features Affect Antiepileptic Drug Therapy Decisions: Focus on Gender, Age, and Psychiatric Comorbidities 79
EFFECTS OF THE ANTIDEPRESSANT DRUG VILOXAZINE ON OXCARBAZEPINE AND ITS HYDROXYLATED METABOLITES IN PATIENTS WITH EPILEPSY 78
COULD LAMOTRIGINE BE USEFUL IN STATUS EPILEPTICUS - A CASE- REPORT 78
Objective cognitive dysfunction assessment in patients with subjective cognitive complaints: does it allow an early differentiation between demnetia and pseudo-dementia? 78
Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients 77
The 894G > T (Glu298Asp) variant in the endothelial NOSgene and MTHFR polymorphisms influence homocysteine levels in patients withcognitive decline. 77
Liquid chromatographic assay of lamotrigine,a new antiepileptic drug, by a hig-speed column 76
The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction 76
Sodium valproate and valpromide:Differential interactions with carbamazepine in epileptic patients 76
Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T polymorphism in Levodopa-treated Parkinson’s disease patients 76
INTERACTION OF LAMOTRIGINE WITH SODIUM VALPROATE 75
Pharmacokinetics of phenylethylmalonamide (PEMA) after oral and intravenous administration 75
LAMOTRIGINE IN RESISTANT CHILDHOOD EPILEPSY 74
Effects of remacemide and lamotrigine on MNDA-induced excitotoxicity in isolated chick embryo retina 74
Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study 74
Valproic acid-ethosuximide interaction: A pharmacokinetic study 74
Increased dipropylacetic acid bioavailability from dipropylacetamide by food 74
CONTRIBUTION OF INTERICTAL BRAIN PERFUSION SPECT IN ASSESSING PATIENTS WITH EPILEPSY 74
Morbidity in patients with epilepsy: type and complications: a European cohort study 73
Principles and current issues of antiepileptic drug therapy 73
CLINICALLY RELEVANT ANTI-EPILEPTIC DRUG-INTERACTIONS 72
THE INFLUENCE OF ELECTROENCEPHALOGRAPHIC FOCUS LATERALITY ON EFFICACY OF CARBAMAZEPINE IN COMPLEX PARTIAL AND SECONDARILY GENERALIZED TONIC-CLONIC SEIZURES 71
The importance of drug interactions in epilepsy therapy 71
Distribution of attention in normal people as a function of spatial location: Right-left, up-down 71
Limited place for plasma monitoring of new antiepileptic drugs in clinicalpractice. 70
LIQUID-CHROMATOGRAPHIC ANALYSIS OF ANTIEPILEPTIC DRUGS - AN OVERVIEW 70
Phenylethylmalonamide in essential tremor.A double-blind controlled study 70
Il contributo della SPECT inter-critica nella valutazione del paziente con epilessia:possibili ulteriori indicazioni sulla base di alcuni casi selezionati 70
VIGABATRIN-INDUCED DECREASE IN SERUM PHENYTOIN CONCENTRATION DOES NOT INVOLVE A CHANGE IN PHENYTOIN BIOAVAILABILITY 69
Neuroprotective effects of lamotrigine and remacemide on excitotoxicity induced by glutamate agonists in isolated chick retina 69
Efficacia della lamotrigina nelle crisi con caduta 69
Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy 69
Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia? Insights from in vitro studies 67
SAFETY AND EFFICACY OF VIGABATRIN AND CARBAMAZEPINE IN NEWLY DIAGNOSED EPILEPSY:A MULTICENTER RANDOMISED DOUBLE-BLIND STUDY 67
Screening for C677T and A1298C MTHFR polymorphisms in patients with epilepsy and risk of hyperhomocysteinemia 67
Totale 9.301
Categoria #
all - tutte 53.624
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.624


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021556 0 0 0 0 0 165 16 105 16 101 91 62
2021/20221.118 19 167 23 42 22 3 66 55 25 152 194 350
2022/20232.741 235 172 96 214 257 257 29 182 1.156 17 80 46
2023/2024637 68 122 60 69 46 130 15 26 2 29 8 62
2024/20253.325 55 45 89 154 158 75 41 962 867 151 188 540
2025/20262.984 268 615 572 764 692 73 0 0 0 0 0 0
Totale 14.151